This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

Graphite Bio Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Graphite Bio prognostiziert ein Gewinnwachstum at 36.4% per annum. Der Gewinn pro Aktie wird voraussichtlich wachsen um 73.8% pro Jahr.

Wichtige Informationen

36.4%

Wachstumsrate der Gewinne

73.8%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	27.3%
Wachstumsrate der Einnahmen	n/a
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	15 Nov 2023

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Gewinn- und Umsatzwachstumsprognosen

NasdaqGM:GRPH - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	N/A	-23	N/A	N/A	1
12/31/2025	N/A	-23	N/A	N/A	1
12/31/2024	N/A	-23	N/A	N/A	1
12/31/2023	N/A	-125	-101	-90	N/A
9/30/2023	N/A	-126	-78	-67	N/A
6/30/2023	N/A	-129	-87	-79	N/A
3/31/2023	N/A	-99	-92	-88	N/A
12/31/2022	N/A	-101	-95	-88	N/A
9/30/2022	N/A	-95	-88	-81	N/A
6/30/2022	N/A	-85	-84	-74	N/A
3/31/2022	N/A	-77	-75	-66	N/A
12/31/2021	N/A	-71	-59	-53	N/A
9/30/2021	N/A	-115	-48	-43	N/A
6/30/2021	N/A	-104	-32	-30	N/A
3/31/2021	N/A	-88	-19	-17	N/A
12/31/2020	N/A	-68	-10	-9	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: GRPH wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: GRPH wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: GRPH wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: Die Daten reichen nicht aus, um festzustellen, ob die Einnahmen von GRPH schneller wachsen werden als der Markt von US.

Hohe Wachstumseinnahmen: GRPH wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von GRPH in 3 Jahren voraussichtlich hoch sein wird

This company is no longer active

Graphite Bio Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target decreased by 23% to US$2.83

Price target decreased to US$10.86

Recent updates

Graphite Bio, Inc.(NasdaqGM:GRPH) dropped from NASDAQ Composite Index

New major risk - Share price stability

Graphite Bio, Inc. Declares Special Dividend, Payable on March 21, 2024

Graphite Bio, Inc. Declares Special Dividend, Payable on March 21, 2024

LENZ Therapeutics, Inc. entered into a definitive merger agreement to acquire Graphite Bio, Inc. (NasdaqGM:GRPH) for approximately $230 million in a reverse merger transaction.

Here's Why We're Watching Graphite Bio's (NASDAQ:GRPH) Cash Burn Situation

Graphite Bio, Inc. Announces Executive Changes

Graphite Bio, Inc. Appoints Kimberlee C. Drapkin as Independent Director

Graphite Bio, Inc Announces Departure of Alethia Young as Chief Financial Officer

Graphite Bio, Inc., Annual General Meeting, Jul 19, 2023

We're Hopeful That Graphite Bio (NASDAQ:GRPH) Will Use Its Cash Wisely

Price target decreased by 23% to US$2.83

Will Graphite Bio (NASDAQ:GRPH) Spend Its Cash Wisely?

Graphite Bio, Inc. Announces Voluntary Pause of Phase 1/2 Cedar Study of Nulabeglogene Autogedtemcel (Nula-Cel) for Sickle Cell Disease

Price target decreased to US$10.86

Graphite Bio, Inc. Presents Preclinical Data for Novel Sequencing Method Used to Determine Gene Editing Outcomes at 64th ASH Annual Meeting

High number of new and inexperienced directors

Here's Why We're Watching Graphite Bio's (NASDAQ:GRPH) Cash Burn Situation

Graphite Bio, Inc. Doses First Patient with Investigational Gene Editing Therapy GPH101 for Sickle Cell Disease

Graphite Bio doses first patient with GPH101 for sickle cell disease

Graphite Bio, Inc.(NasdaqGM:GRPH) dropped from Russell 2500 Value Index

Will Graphite Bio (NASDAQ:GRPH) Spend Its Cash Wisely?

Graphite Bio: Selling For Much Less Than Net Cash

Graphite Bio, Inc. Presents Preclinical Gene Replacement Data for GPH102 for Beta-Thalassemia at the ASGCT 25 Annual Meeting

Graphite Bio, Inc., Annual General Meeting, Jun 21, 2022

High number of new and inexperienced directors

Graphite Bio, Inc. Announces Management Changes

Graphite Bio, Inc. Announces Executive Changes

High number of new and inexperienced directors

Graphite Bio, Inc. Presents Overview of Phase 1/2 CEDAR Trial Evaluating Investigational Gene Editing Therapy GPH101 in Sickle Cell Disease at 63rd ASH Annual Meeting and Exposition

Graphite Bio: An Important Stock To Track In The Gene Editing Space

Graphite Bio (NASDAQ:GRPH) Is In A Good Position To Deliver On Growth Plans

Graphite Bio: Assessing Prospects Amid Doubts Raised On Safety Of Crispr

Graphite Bio, Inc. has completed an IPO in the amount of $238 million.

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken